Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Dis Esophagus ; 20(1): 12-8, 2007.
Article in English | MEDLINE | ID: mdl-17227304

ABSTRACT

Little is known concerning the role of concurrent chemoradiation (CCRT) in the management of carcinoma of the cervical esophagus. We retrospectively evaluated our treatment approach for patients with cervical esophageal cancer with special emphasis on CCRT with or without surgery. Medical records of 21 consecutive patients with cervical esophageal carcinoma treated mainly with CCRT (1997-2004) were reviewed, and factors that influenced patient survival were analyzed retrospectively. Nineteen received CCRT with cisplatin/5-fluorouracil and five underwent curative surgery. Two patients who were deemed unfit for CCRT received radiation therapy alone. All had three-dimensional treatment planning (median total dose, 40 Gy with surgery, 64 Gy without surgery). Of the 19 patients who received CCRT, 11 patients including five who underwent curative surgery achieved initial local control. Neither of the two patients who received radiation therapy alone achieved local control. Among 19 patients who underwent CCRT, 9/11 with T1-3 grade tumors achieved initial local control, but only 2/8 patients with T4 tumors (P = 0.011, chi(2) test) achieved initial local control. No patient without initial local control survived > 20 months compared with 2-year and 5-year survival rates of 60% and 40% in those who achieved initial local control (P = 0.038). No patient with T4 tumors survived > 18 months, whereas 2- and 5-year survival rates were 62% and 41%, respectively, in those with T1-3 tumors (P = 0.006). The significant effect of T-classification on survival was maintained when analyzed among 19 patients who received CCRT. CCRT shows promise for cervical esophageal carcinoma. T-classification and initial local control had significant impact on survival.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/therapy , Esophageal Neoplasms/therapy , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Esophageal Neoplasms/mortality , Esophageal Neoplasms/pathology , Esophagectomy , Female , Fluorouracil/administration & dosage , Follow-Up Studies , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local , Radiotherapy, Adjuvant , Retrospective Studies
2.
Int J Impot Res ; 14(4): 251-5, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12152113

ABSTRACT

This study was conducted to show the effect of sildenafil on electrostimulation-induced erection in the rat model. Fifteen 12-week-old male Wistar Kyoto rats were used. The intracavernous pressure and arterial blood pressure were simultaneously monitored through electric cavernous nerve stimulation before and after the administration of sildenafil (2 mg/kg). Statistical analysis was performed on maximal intracavernous pressure (MIP), mean arterial blood pressure (MAP), the MIP/MAP and detumescence time. MAP decreased significantly by about 20 mmHg after sildenafil administration. The MIP/MAP increased significantly after sildenafil administration. The effect of sildenafil on the MIP/MAP was marked especially at lower (2-3 Hz) frequencies. The detumescence time significantly increased after sildenafil administration. We have shown that sildenafil is effective for enhancing erection at lower frequencies and prolonging penile erection in rats. After the administration of sildenafil, penile erection would be induced by weak stimuli that will not cause penile erection under normal conditions.


Subject(s)
Penile Erection/drug effects , Piperazines/pharmacology , Vasodilator Agents/pharmacology , Animals , Blood Pressure , Electric Stimulation , Male , Models, Animal , Purines , Rats , Rats, Inbred WKY , Sildenafil Citrate , Sulfones
3.
Cancer ; 92(7): 1775-82, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11745249

ABSTRACT

BACKGROUND: Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma. Anthracycline-based regimens represent the standard of treatment for IBC. Reports of significant clinical activity of paclitaxel in metastatic breast carcinoma led the authors to investigate the role of this drug in the management of IBC. METHODS: Forty-four patients with IBC were enrolled between February 1994 and January 1998. The treatment plan consisted of induction chemotherapy (IC), mastectomy, adjuvant chemotherapy, and radiotherapy. Forty-two patients received IC with four cycles of fluorouracil, doxorubicin, and cyclophosphamide. If the clinical response was less than partial, patients were "crossed over" to paclitaxel before mastectomy. All patients received adjuvant paclitaxel. Patients unresectable after paclitaxel were offered high-dose chemotherapy with autologous peripheral blood progenitor cell support. RESULTS: Thirty-four patients (81%) achieved an objective clinical remission; 3 patients (7%) achieved a clinical complete remission, 31 (74%) a partial remission. Six patients (14%) achieved pathologic complete remission. Sixteen patients were treated with paclitaxel, 7 of them (44%) were able to undergo mastectomy. Median time to progression (TTP) was 22 months. Median overall survival (OS) was 46 months. Concordance between clinical and pathologic response was documented in only 8 patients (24%). No differences in TTP and OS compared with a historical group of 178 IBC patients treated with anthracycline-based regimens. CONCLUSIONS: Paclitaxel improves tumor resectability in anthracycline-refractory IBC. The impact of paclitaxel on the prognosis of IBC needs to be better evaluated in future trials using more dose-intensive schedules of administration. New imaging modalities may contribute to improve assessment of response to IC.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Paclitaxel/therapeutic use , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , Mastectomy , Middle Aged , Remission Induction , Survival Analysis
5.
Gastroenterology ; 120(2): 337-45, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11159873

ABSTRACT

BACKGROUND & AIMS: : Ghrelin, an endogenous ligand for growth hormone secretagogue receptor, was recently identified in the rat stomach. We examined the effects of the gastric peptide ghrelin on energy balance in association with leptin and vagal nerve activity. METHODS: : Food intake, oxygen consumption, gastric emptying, and hypothalamic neuropeptide Y (NPY) messenger RNA expression were measured after intra-third cerebroventricular or intraperitoneal injections of ghrelin in mice. The gastric vagal nerve activity was recorded after intravenous administration in rats. Gastric ghrelin gene expression was assessed by Northern blot analysis. Repeated coadministration of ghrelin and interleukin (IL)-1 beta was continued for 5 days. RESULTS: : Ghrelin exhibited gastroprokinetic activity with structural resemblance to motilin and potent orexigenic activity through action on the hypothalamic neuropeptide Y (NPY) and Y(1) receptor, which was lost after vagotomy. Ghrelin decreased gastric vagal afferent discharge in contrast to other anorexigenic peptides that increased the activity. Ghrelin gene expression in the stomach was increased by fasting and in ob/ob mice, and was decreased by administration of leptin and IL-1 beta. Peripherally administered ghrelin blocked IL-1 beta-induced anorexia and produced positive energy balance by promoting food intake and decreasing energy expenditure. CONCLUSIONS: : Ghrelin, which is negatively regulated by leptin and IL-1 beta, is secreted by the stomach and increases arcuate NPY expression, which in turn acts through Y(1) receptors to increase food intake and decrease energy expenditure. Gastric peptide ghrelin may thus function as part of the orexigenic pathway downstream from leptin and is a potential therapeutic target not only for obesity but also for anorexia and cachexia.


Subject(s)
Appetite/physiology , Motilin/genetics , Peptide Hormones , Peptides/genetics , Peptides/pharmacology , Stomach/physiology , Amino Acid Sequence , Animals , Blotting, Northern , Electrophysiology , Energy Metabolism/drug effects , Energy Metabolism/physiology , Feeding Behavior/drug effects , Feeding Behavior/physiology , Gastric Emptying/drug effects , Gastric Emptying/physiology , Gene Expression/physiology , Ghrelin , Hypothalamus/physiology , Injections, Intraventricular , Interleukin-1/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Molecular Sequence Data , Motilin/chemistry , Neuropeptide Y/genetics , Oxygen Consumption/drug effects , Oxygen Consumption/physiology , Peptides/chemistry , RNA, Messenger/analysis , Rats , Rats, Wistar , Receptors, Gastrointestinal Hormone/genetics , Receptors, Neuropeptide/genetics , Stomach/innervation , Vagus Nerve/drug effects , Vagus Nerve/physiology
6.
Gastroenterology ; 117(6): 1427-32, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10579984

ABSTRACT

BACKGROUND & AIMS: Pancreatic polypeptide (PP) is a 36-amino acid hormone produced by F cells within the pancreatic islets and the exocrine pancreas. The definitive function of PP in mammalian physiology remains to be determined. This study examined the effects of chronic overexpression of PP through the development of PP transgenic mice. METHODS: PP transgenic mice were created by using mouse PP complementary DNA under the control of the cytomegalovirus immediate early enhancer-chicken beta-actin hybrid promoter (pCAGGS expression vector). RESULTS: A unique line of transgenic mice was created that overexpresses PP in the pancreatic islets with low levels of expression in other tissues including the brain. Plasma PP concentrations were more than 20 times higher than those of control littermates. However, PP overproduction led to postnatal lethality in half of the pups because of markedly decreased milk intake. The remaining PP transgenic mice gained less weight with specifically reduced food intake and fat mass compared with controls, a result that was more evident in male than in female mice. The transgenic mice exhibited a reduced rate of gastric emptying of a solid meal but had normal oxygen consumption and fasting leptin levels. Immunoneutralization with anti-PP antiserum reversed the phenotypic changes of transgenic animals. CONCLUSIONS: PP could be involved in feeding and body weight regulation partly through regulation of gastric emptying.


Subject(s)
Body Weight/physiology , Eating/physiology , Pancreatic Polypeptide/physiology , Animals , DNA, Complementary/genetics , Female , Islets of Langerhans/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Pancreatic Polypeptide/biosynthesis , Pancreatic Polypeptide/genetics
7.
Biochem Biophys Res Commun ; 232(1): 126-9, 1997 Mar 06.
Article in English | MEDLINE | ID: mdl-9125115

ABSTRACT

We identified a novel Drosophila gene, Dpkn (Drosophila protein kinase related to PKN), encoding a putative protein serine/threonine kinase. Although the cDNA obtained was incomplete at its 5'-terminal region, the deduced amino acid sequence of its kinase domain exhibits a high degree of similarity to protein kinase N (PKN), which has a kinase domain related to protein kinase C (PKC) and leucine zipper-like sequences in the amino terminal region. Expression of Dpkn was observed throughout Drosophila development, although its expression level decreased at later stages of embryogenesis. The expression of Dpkn is first detected in the newly formed mesodermal cell layer and is then restricted to the developing somatic musculature, indicating a possible role of Dpkn in the development of somatic muscles in Drosophila.


Subject(s)
Drosophila/genetics , Protein Kinase C/genetics , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern , Cloning, Molecular , DNA, Complementary , Drosophila/enzymology , Humans , Molecular Sequence Data , RNA/genetics , RNA/metabolism , Sequence Homology, Amino Acid
8.
Biochem Biophys Res Commun ; 214(2): 432-9, 1995 Sep 14.
Article in English | MEDLINE | ID: mdl-7677748

ABSTRACT

Using conserved nucleotide sequences in mammalian osteoblast specific factor-1 (OSF-1) coding regions, we isolated two kinds of cDNA clones from the Xenopus brain library. The encoded proteins, named Xenopus pleiotrophic factors (X-PTFs)-alpha and -beta, were 65 and 87% homologous to human midkine and OSF-1, respectively. In the adult frog, X-ptf-alpha was expressed in the ovary, brain, eye, bone, heart and lung, whereas X-ptf-beta was expressed in the brain, eye and bone. By in situ hybridization of the tailbud embryo, X-ptf-alpha mRNA was detected rather broadly in the head/tail regions including the central nervous system (CNS), whereas X-ptf-beta mRNA was restricted to the CNS, particularly in the hind-brain. During embryogenesis, X-ptf-alpha mRNA was detected in the one-cell stage embryo, whereas only zygotic expression was observed in X-ptf-beta. X-ptf-beta mRNAs contained approximately 79 bp tandem repeats in the 3'-untranslated region, complementary to those found in retinoic acid cellular receptor mRNA and in the sense strand of short interspersed repeat transcripts in X. laevis.


Subject(s)
Carrier Proteins/biosynthesis , Cytokines/biosynthesis , Embryo, Nonmammalian/physiology , Gene Expression Regulation , Mesoderm/physiology , Aging , Amino Acid Sequence , Animals , Base Sequence , Carrier Proteins/chemistry , Cattle , Conserved Sequence , Cytokines/chemistry , DNA Primers , Female , Growth Substances/biosynthesis , Humans , Mice , Midkine , Molecular Sequence Data , Organ Specificity , Polymerase Chain Reaction , Sequence Homology, Amino Acid , Transcription, Genetic , Xenopus laevis
9.
Hinyokika Kiyo ; 38(10): 1165-9, 1992 Oct.
Article in Japanese | MEDLINE | ID: mdl-1481777

ABSTRACT

A 58-year-old male patient was admitted to the hospital complaining of weight loss. Abdominal computerized tomographic (CT) scan disclosed a mass shadow in the left kidney. From the results of further examination, including drip infusion pyelography (DIP) and angiography, he was preoperatively diagnosed as having a left renal tumor. Left radical nephrectomy was performed on March 15, 1990. The lesion was histologically diagnosed as renal cell carcinoma (clear cell subtype, grade 2) confined by the renal capsule (stage I). No distant metastases were detected. Interferon-alpha was administered every other day as adjuvant chemotherapy. After the patient experienced muscle pain in his thighs and shoulders after exercise on February 11, 1991, the serum creatine phosphokinase (CPK) level progressively increased up to 2,329 U/l. On the basis of the results of various examinations reflecting thyroid gland function, he was diagnosed as having primary hypothyroidism due to Hashimoto's disease. Thyroid function improved after administration of triiodothyronine and thyroxine. Interferon has been reported to influence thyroid function, and, in this case, interferon-alpha therapy may have induced the primary hypothyroidism associated with Hashimoto's disease.


Subject(s)
Hypothyroidism/etiology , Interferon-alpha/adverse effects , Kidney Neoplasms/therapy , Chemotherapy, Adjuvant , Creatine Kinase/blood , Humans , Hypothyroidism/diagnosis , Hypothyroidism/drug therapy , Interferon-alpha/therapeutic use , Kidney Neoplasms/surgery , Male , Middle Aged , Nephrectomy , Thyroid Function Tests , Thyroid Hormones/administration & dosage , Thyroiditis, Autoimmune/complications
10.
Acta Physiol Scand ; 134(2): 253-61, 1988 Oct.
Article in English | MEDLINE | ID: mdl-2465673

ABSTRACT

The insulinotropic and glucagon-releasing activity of acid extracts of rat hypothalami were tested in two bioassay systems using short-time incubation of isolated rat pancreatic islets and a rat insulinoma (RIN) cell line. Release of insulin and glucagon into the incubation medium was measured by radioimmunoassay. The major insulin-releasing and glucagon-releasing activity eluted in a broad zone in Sephacryl S-200 gel filtration in 30% acetic acid corresponding to the molecular weights between approximately 10 and 40 kD. The highest activity was eluted in a zone corresponding to 14 kD and was purified to homogeneity by means of two steps of reversed-phase HPLC. Amino acid analysis and SDS polyacrylamide gel electrophoresis indicated that the biologically active material was the rat small (myelin) basic protein characterized previously by Dunkley & Carnegie (1974). The purified rat hypothalamic material showed insulinotropic and glucagon-releasing activity indistinguishable from that of purified porcine myelin basic protein, and lost its insulinotropic activity when incubated with anti-myelin basic protein immunosorbent. We conclude that the major insulin-releasing and glucagon-releasing activity in acid extracts of the high-molecular-weight fractions of rat hypothalami is myelin basic protein.


Subject(s)
Glucagon/metabolism , Hypothalamus/analysis , Insulin/metabolism , Islets of Langerhans/metabolism , Myelin Basic Protein/administration & dosage , Tissue Extracts/administration & dosage , Amino Acids/analysis , Animals , Biological Assay , Cell Line, Transformed , Insulin Secretion , Insulinoma/metabolism , Molecular Weight , Myelin Basic Protein/isolation & purification , Neutralization Tests , Pancreatic Neoplasms/metabolism , Radioimmunoassay , Rats , Tissue Extracts/analysis
SELECTION OF CITATIONS
SEARCH DETAIL